Abstract 3461: Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3461
Abstract: Background: KRAS mutations (mt) are found in ~30% of non-small cell lung cancers (NSCLC). Despite the approval and development of KRAS G12C and KRAS G12D inhibitors respectively, mechanisms of resistance to MAPK pathway inhibitors are… read more here.
Keywords: avutometinib everolimus; kras nsclc; combination; mek ... See more keywords
Role of KRAS in NSCLC: present and future
Sign Up to like & getrecommendations! Published in 2018 at "Genetics and Molecular Research"
DOI: 10.4238/gmr16039873
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Despite therapeutic advances over the last several decades, the overall 5-year survival remains only 16%. (Siegel R, 2013). Molecular studies have indicated that Adenocarcinomas have… read more here.
Keywords: kras nsclc; nsclc present; cancer; present future ... See more keywords